14 results about "Prothrombase" patented technology

A clinical decision support device, comprising: a parameter acquisition module, configured to acquire measured values for markers in a biomarker combination of a subject, wherein the biomarker combination at least comprises an alpha fetoprotein, an abnormal prothrombin, γ-glutamyltransferase, and an albumin; a risk assessment module, configured to input the measured values for the markers in the biomarker combination into a calculation model to obtain an output of the calculation model as a liver cancer risk prediction result of the subject; and an output module, configured to output the liver cancer risk prediction result of the subject. Also disclosed are a sample analysis system and a method for assessing a liver cancer risk of a subject, capable of better assessing a liver cancer risk of a subject.

The invention relates to the use of prethrombin-1 as a drug.

A fully-printed sensor chip for measuring prothrombin time of a blood sample. The sensor chip includes a pair of electrodes and a pair of contact pads, each electrically coupled to a different one of the electrodes, printed on the surface of the substrate using conductive ink materials. When a blood sample is placed on the sample chip in contact with both electrodes, an impedance of the blood sample is determined based on a measured impedance between the two contact pads. As the blood sample clots, the impedance value changes and the prothrombin time for the blood sample is determined based on a measurement time of a maximum impedance value. A resistive bridge printed on the substrate surface between the contact pads increases a baseline measurement for the sensor chip to a value within a range that is measurable by lower-cost measurement equipment.

The present invention relates to sample analysis cartridges comprising micro-environment sensors and methods for assaying coagulation in a fluid sample applied to the micro-environment sensors, and in particular, to performing coagulation assays using micro-environment sensors in a point of care sample analysis cartridge. For example, the present invention may be directed to a sample analysis cartridge including an inlet chamber configured to receive a biological sample, and a conduit fluidically connected to the inlet chamber and configured to receive the biological sample from the inlet chamber. The conduit may include a micro-environment prothrombin time (PT) sensor, and a micro-environment activated partial thromboplastin time (aPTT) sensor.

The invention belongs to biomedical materials, and particularly relates to an antibacterial and anticoagulant coating material for a blood contact material and application of the antibacterial and anticoagulant coating material. The antibacterial and anticoagulant coating material comprises copper tetracarboxyl phenyl porphyrin loaded with an anticoagulant and water-soluble polysaccharide. A coating formed on the basis of the antibacterial and anticoagulant coating material can achieve antibacterial and anticoagulant effects at the same time, for example, the bacteriostasis rate on escherichia coli and the bacteriostasis rate on staphylococcus epidermidis can reach 90%; in addition, the activated part thromboplastin time, prothrombin time and thrombin time of the coating are obviously higher than those of an untreated blood contact material; and the hemolysis rate is lower than 5%.

The invention discloses a chronic hepatitis B related disease process prediction method based on the ratio of PLG to PT. The method comprises the following steps: S1, sample collection: collecting sodium citrate anticoagulant venous blood of a to-be-predicted object; s2, index detection: detecting the plasminogen level in the plasma by adopting a chromophoric substrate method, and detecting the prothrombin time in the plasma by adopting a coagulation method; s3, specific value calculation: calculating the specific value of PLG to PT, wherein the specific value is used as a core prediction index of the chronic hepatitis B related end-stage liver disease process; and S4, process judgment: judging a disease process stage of the to-be-predicted object according to the PLG / PT ratio in combination with a preset threshold value. The method has the beneficial effects that the ratio of the PLG to the PT is used as a core prediction index. The specific value integrates dual information of liver synthesis function and blood coagulation fibrinolysis system imbalance, the scientificity of indexes is ensured, the design logic of the specific value is different from that of any existing verification method, and the crossing from single-dimensional detection to multi-dimensional integration evaluation is realized.

The invention belongs to the field of basic medicine, and particularly relates to a method for establishing a blood coagulation disorder animal model, which comprises the following steps of: performing intragastric administration on a healthy rat with a preparation containing podophyllotoxin according to the dose of 10mg / kg per day, and continuously performing administration for 4 days; wherein the drug administration can induce the rat to generate blood coagulation disorder phenotypes, and the phenotypes at least comprise prothrombin time prolonging, activated partial thromboplastin time prolonging and thrombin time prolonging. According to the establishment method of the blood coagulation disorder animal model, it is determined that podophyllotoxin can cause whole-body blood coagulation disorder, and the stable and repeatable blood coagulation disorder animal model is provided.

The invention discloses an in-vitro sample detection data-based decompensated liver cirrhosis risk assessment method and a related device, and relates to the technical field of liver cirrhosis condition assessment. The method comprises the following steps: acquiring in-vitro detection sample data corresponding to a to-be-assessed blood sample, the in-vitro detection sample data comprises sCD146, prothrombin time, serum albumin and platelet count; performing data preprocessing on the in-vitro detection sample data, namely generating a serum albumin grade variable ALBgrade based on a preset grading threshold value according to the numerical value of the serum albumin; inputting the processed feature data into a pre-trained binary Logistic regression model, and outputting a decompensated liver cirrhosis risk value corresponding to the to-be-evaluated blood sample; the decompensated liver cirrhosis risk value is a prediction probability P output by the binary Logistic regression model. The method can effectively improve the evaluation accuracy of decompensated liver cirrhosis.

This application relates to a clinical decision support device, comprising: a parameter acquisition module configured to acquire the measured values ​​of each biomarker in a biomarker combination of a subject, wherein the biomarker combination includes at least alpha-fetoprotein, abnormal prothrombin, gamma-glutamyl transferase, and albumin; a risk assessment module configured to input the measured values ​​of each biomarker in the biomarker combination into a computational model, and obtain the output of the computational model as a liver cancer risk prediction result for the subject; and an output module configured to output the liver cancer risk prediction result for the subject. This application also relates to a sample analysis system and a method for assessing the liver cancer risk of a subject. This application enables improved assessment of the liver cancer risk of a subject.

The invention discloses an extraction and separation method of anise polysaccharide with anticoagulant activity. The method comprises the following steps: crushing fresh anise, extracting with hot water, concentrating a water extract, and adding ethanol for precipitation to obtain crude polysaccharide; removing protein by adopting a Sevage method; and dialyzing to remove small molecular impurities, and freeze-drying to obtain the purified anise polysaccharide. The molecular weight of the polysaccharide is about 72.053 kDa. In-vitro coagulation experiments show that the polysaccharide can significantly prolong prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) and reduce the content of fibroblast egg (FIB) white, and shows significant anticoagulant activity. The star anise polysaccharide provided by the invention can be used for preparing anticoagulant drugs, and has the advantages of wide raw material source, simple extraction process, definite activity and the like.

The invention discloses a method for predicting the lactic acid rise risk of a patient with sepsis with acute lung injury, and the method is to construct a model for predicting the lactic acid rise risk of the patient with sepsis with acute lung injury, and the model comprises the following indexes: chronic obstructive pulmonary disease, anion gap (AG), artery pH and prothrombin time (PT). The prediction method provided by the invention has relatively good distinction degree and accuracy for predicting the lactic acid rise risk of the sepsis with acute lung injury ICU patient, has relatively high practicability and applicability clinically, and is helpful for a clinician to early identify the sepsis with acute lung injury ICU patient with high risk of lactic acid rise; corresponding means are timely adopted for treatment intervention, so that the pain of the patient is relieved, the life quality of the patient is improved, and the application prospect is wide.

The invention discloses a method for detecting abnormal prothrombin PIVKA-II, and belongs to the technical field of medicine and biologica.The method comprises the following steps that S1, a PIVKA-II antibody coated with luminous particles is prepared; s2, a biotin labeled PIVKA-II antibody is prepared; s3, preparing a PIVKA-II calibrator and establishing a standard curve; and S4, detecting. The detection method disclosed by the invention has the characteristics of high sensitivity, good specificity, strong stability and simplicity in operation.

This invention discloses the application of sodium thiocyanate in the preparation of a kit for coagulation assays. The kit detects coagulation parameters based on coagulation methods, chromogenic substrate methods, or immunoturbidimetric assays. These coagulation parameters include prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, fibrin(ogen) degradation products, D-dimer, antithrombin III, and anti-Xa. By adding sodium thiocyanate to the coagulation assay kit, this invention optimizes the clinical relevance of the assay kit by adjusting reaction time (coagulation method), improving the linear range (chromogenic substrate method), and enhancing the differentiation between low and high values ​​(immunoturbidimetric assay), thereby improving the accuracy of the test.

The invention discloses a model for early prediction of acute kidney injury risk after a sepsis patient is transferred into ICU based on clinical variables and immune inflammation indicators, and an immune-clinical model is established by adopting an XGBoost algorithm based on data of 1551 domestic sepsis patients in 24 hours after the sepsis patient is transferred into the ICU so as to predict the risk of SA-AKI of the patient. The model integrates five clinical variables including procalcitonin, APACHE II, SOFA score, gender and prothrombin time and four immune inflammation indexes including IgA, complement C3, Nave CD4 + T% and CD28 + CD4 + T%, the average ROC-AUC value is 0.914, an SHAP method is introduced to generate a feature importance map and an individual prediction interpretation map, the contribution degree of each index to risk prediction of a specific patient can be visually displayed, the cause of SA-AKI of the patient can be explained, and the risk of the specific patient can be predicted. Therefore, doctors can take targeted measures preventively.